parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.07 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced in oligodendrocytes (3 nCPM)	1.00
chemistry Open Targets	reachable by antibody	0.45
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 169	0.91
pathways Reactome	1 pathway; mostly other	0.30

No case: the score is under the bar. Receipt 4039

CLDN11 in dopamine neurons, braak+0.21 (p 0.586) → +0.00 (p 1.000)receipt 4046
CLDN11 in oligodendrocytes, braak+0.00 (p 1.000) → +0.28 (p 0.464)receipt 4045

receipt 4046: CLDN11 in dopamine neurons, braak

power: full sample +0.08 (p 0.741, n 18), 95% CI -0.40 to +0.53. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.10 (p 0.696, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: +0.30 (p 0.221, n 18). could be the mix.
skeptic: leave-one-out range -0.03 to +0.22, sign flips 2; without severely affected donors +0.08 (p 0.741, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CLDN11 in dopamine neurons.

case closed: nothing better to follow up.

receipt 4045: CLDN11 in oligodendrocytes, braak

power: full sample +0.05 (p 0.834, n 18), 95% CI -0.42 to +0.51. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.04 (p 0.881, n 18). does not hold up.
composition: oligodendrocytes share of nuclei vs axis +0.03 (p 0.915); controlling for it: -0.00 (p 0.990, n 18). could be the mix.
skeptic: leave-one-out range -0.03 to +0.20, sign flips 4; without severely affected donors +0.05 (p 0.834, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CLDN11 in oligodendrocytes.

case closed: nothing better to follow up.

loading the receipts